TCT 364: FANTOM II Long Lesion Study: Initial Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold in Long Lesions: 5 Clinical Year Outcomes

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• Consultant Fee/Honoraria/Speaker’s Bureau - Abbott Vascular; REVA Medical; AstraZenca; CardiacDimensions